Clinical Trial

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-18.
Trial Details
NCT Number NCT07039578
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Primary Light-Chain Amyloidosis
Enrollment 90 participants
Start Date 2025-07-25
Primary Completion 2026-06-30 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-26